FIGURE 1.

Participant marstacimab dose assignments. Participants from Cohorts 1 and 4 in the previous study continued to receive 300 mg weekly, and Cohorts 2 and 3 in the previous study received the lowest dose determined to be safe and effective (300‐mg loading dose followed by 150 mg SC weekly). Two participants were recruited de novo into the present study. Both were treated at the lowest effective dose level (300‐mg loading dose followed by 150 mg SC weekly). SC, subcutaneous; QW, once weekly